ResMed CFO Sandercock reports 2,710-share performance award vesting

Rhea-AI Filing Summary

ResMed Inc. (RMD) Chief Financial Officer Brett Sandercock reported an equity award vesting. On 11/20/2025, he acquired 2,710 shares of ResMed common stock at a price of $0 per share, reflecting the earning of performance-based restricted stock units originally granted on 11/16/2022. The compensation and leadership development committee certified that the required performance metrics were met, which triggered the share delivery.

Following this transaction, Sandercock beneficially owns 88,495 shares of ResMed common stock in direct ownership. This filing is a routine disclosure of insider equity compensation vesting and does not indicate an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sandercock Brett

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	ResMed Common Stock	2,710	$0.00	--

Holdings After Transaction: ResMed Common Stock — 88,495 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandercock Brett

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	11/20/2025		A(1)		2,710	A	$0	88,495	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents performance-based restricted stock units granted on November 16, 2022. The shares were earned on November 20, 2025, when the compensation and leadership development committee certified that the performance metrics were met.

	Brett Sandercock, Chief Financial Officer	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ResMed (RMD) disclose for its CFO?

ResMed disclosed that its Chief Financial Officer, Brett Sandercock, acquired 2,710 shares of ResMed common stock on 11/20/2025 from the vesting of performance-based restricted stock units at a price of $0 per share.

How many ResMed (RMD) shares does the CFO own after this Form 4 transaction?

After the reported transaction, CFO Brett Sandercock beneficially owns 88,495 shares of ResMed common stock in direct ownership.

What was the source of the 2,710 ResMed (RMD) shares reported on the Form 4?

The 2,710 shares represent performance-based restricted stock units granted on 11/16/2022, which were earned when the compensation and leadership development committee certified on 11/20/2025 that the performance metrics were met.

Did the ResMed (RMD) CFO pay cash for the newly acquired shares?

No. The 2,710 shares were acquired at a reported price of $0 per share as a result of performance-based restricted stock units vesting, rather than an open-market purchase.

Does this ResMed (RMD) Form 4 indicate an open-market sale by the CFO?

No. The Form 4 reports the acquisition of 2,710 shares through vesting of performance-based restricted stock units, with no sale of shares reported in the provided content.

What role does the committee play in the ResMed (RMD) CFO’s equity awards?

The compensation and leadership development committee certifies whether performance metrics tied to the CFO’s performance-based restricted stock units have been met. On 11/20/2025, it certified those metrics, causing the 2,710 shares to be earned.